orantinib has been researched along with afimoxifene in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (afimoxifene) | Trials (afimoxifene) | Recent Studies (post-2010) (afimoxifene) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 1,255 | 10 | 325 |
| Protein | Taxonomy | orantinib (IC50) | afimoxifene (IC50) |
|---|---|---|---|
| Phospholipase D2 | Homo sapiens (human) | 6.5 | |
| Estrogen receptor | Homo sapiens (human) | 0.0105 | |
| Estrogen-related receptor gamma | Homo sapiens (human) | 0.0084 | |
| Phospholipase D1 | Homo sapiens (human) | 6.5 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.0102 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evan, GI; Fox, SB; Harris, AL; Knies-Bamforth, UE; Poulsom, R | 1 |
1 other study(ies) available for orantinib and afimoxifene
| Article | Year |
|---|---|
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
Topics: Animals; Cell Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Keratinocytes; Mice; Neovascularization, Physiologic; Oxindoles; Papilloma; Precancerous Conditions; Propionates; Proto-Oncogene Proteins c-myc; Pyrroles; RNA, Messenger; Skin; Skin Neoplasms; Tamoxifen; Transcription Factors; Transgenes; Vascular Endothelial Growth Factor A | 2004 |